PMID: 1452087Nov 1, 1992Paper

Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide

Gut
F H MouradM J Farthing

Abstract

A 22 year old insulin dependent diabetic with high volume, secretory chronic diarrhoea refractory to standard andiarrhoeal drugs was treated with the somatostatin analogue octreotide, 50 micrograms twice daily by subcutaneous injection. She improved markedly with a decrease in mean stool weight from 1170 g/24 h range 440-2900 g) to 440 g/24 h (range 180-800 g) (p < 0.05). Stool frequency also decreased from six (range two to 12) to one (range one to three) bowel movements per day (p < 0.01). Mouth to caecum transit time increased from 45 minutes to > 210 minutes, although total gut transit time was unchanged and remained rapid at nine hours. Thus octreotide can reduce stool volume and frequency in high volume diabetic diarrhoea when conventional antidiarrhoeal agents have failed. Its therapeutic benefit appeared to be predominantly related to a marked increase in mouth to caecum transit time.

Associated Clinical Trials

References

Feb 1, 1979·Archives of Neurology·J BrahamI Sarova-Pinhas
Jun 1, 1986·Annals of Internal Medicine·S T TsaiJ F Brunner
Jan 1, 1987·Gastroenterology·A M MetcalfB G Wolff
Feb 1, 1985·Annals of Internal Medicine·R N FedorakE B Chang
Oct 1, 1980·The Journal of Clinical Investigation·K DharmsathaphornJ W Dobbins
Dec 1, 1982·Journal of Clinical Gastroenterology·K DharmsathaphornJ W Dobbins
Mar 1, 1983·Annals of Internal Medicine·M Feldman, L R Schiller
Dec 1, 1984·Annals of Internal Medicine·J S Goff

❮ Previous
Next ❯

Citations

Oct 1, 1995·Diabetes/metabolism Reviews·V SpalloneG Menzinger
Sep 22, 2009·Current Gastroenterology Reports·Milena Gould, Joseph H Sellin
Feb 13, 2008·Nature Clinical Practice. Gastroenterology & Hepatology·Joseph H Sellin, Eugene B Chang
Dec 12, 2001·Alimentary Pharmacology & Therapeutics·A Szilagyi, I Shrier
Jan 1, 1994·Gut·M J Farthing
Jun 5, 2007·Best Practice & Research. Clinical Gastroenterology·Michael J G Farthing
Oct 14, 2005·Obesity Research·Filippo CremoniniDuane Burton
Dec 6, 2003·Internal Medicine Journal·C MeyerA J Jenkins
Aug 28, 2009·Diabetic Medicine : a Journal of the British Diabetic Association·A Corbould, J Campbell
Sep 17, 2015·Current Diabetes Reports·Viktor József HorváthTamás Várkonyi
Jul 1, 1994·The British Journal of Surgery·P M SagarB A Taylor
Oct 25, 2017·Current Treatment Options in Gastroenterology·Marc S Piper, Richard J Saad
Sep 22, 2019·Digestive Diseases and Sciences·Alexandra SelbyFrank K Friedenberg
Oct 1, 1996·Annals of Tropical Medicine and Parasitology·Z AbbasS Hamid
Jun 1, 1994·Baillière's Clinical Gastroenterology·P N Maton
Aug 7, 2021·The Journal of General Physiology·Alexandre G VougaBrad S Rothberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.